Form 8-K

8-K — GeneDx Holdings Corp.

Accession: 0001628280-26-051852

Filed: 2026-08-03

Period: 2026-08-03

CIK: 0001818331

SIC: 8000 (SERVICES-HEALTH SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — wgs-20260803.htm (Primary)

EX-99.1 (exhibit991-q22026pressrele.htm)

EX-99.2 (q22026earningspresentati.htm)

GRAPHIC (genedxlogo.jpg)

GRAPHIC (q22026earningspresentati001.jpg)

GRAPHIC (q22026earningspresentati002.jpg)

GRAPHIC (q22026earningspresentati003.jpg)

GRAPHIC (q22026earningspresentati004.jpg)

GRAPHIC (q22026earningspresentati005.jpg)

GRAPHIC (q22026earningspresentati006.jpg)

GRAPHIC (q22026earningspresentati007.jpg)

GRAPHIC (q22026earningspresentati008.jpg)

GRAPHIC (q22026earningspresentati009.jpg)

GRAPHIC (q22026earningspresentati010.jpg)

GRAPHIC (q22026earningspresentati011.jpg)

GRAPHIC (q22026earningspresentati012.jpg)

GRAPHIC (q22026earningspresentati013.jpg)

GRAPHIC (q22026earningspresentati014.jpg)

GRAPHIC (q22026earningspresentati015.jpg)

GRAPHIC (q22026earningspresentati016.jpg)

GRAPHIC (q22026earningspresentati017.jpg)

GRAPHIC (q22026earningspresentati018.jpg)

GRAPHIC (q22026earningspresentati019.jpg)

GRAPHIC (q22026earningspresentati020.jpg)

GRAPHIC (q22026earningspresentati021.jpg)

GRAPHIC (q22026earningspresentati022.jpg)

GRAPHIC (q22026earningspresentati023.jpg)

GRAPHIC (q22026earningspresentati024.jpg)

GRAPHIC (q22026earningspresentati025.jpg)

GRAPHIC (q22026earningspresentati026.jpg)

GRAPHIC (q22026earningspresentati027.jpg)

GRAPHIC (q22026earningspresentati028.jpg)

GRAPHIC (q22026earningspresentati029.jpg)

GRAPHIC (q22026earningspresentati030.jpg)

GRAPHIC (q22026earningspresentati031.jpg)

GRAPHIC (q22026earningspresentati032.jpg)

GRAPHIC (q22026earningspresentati033.jpg)

GRAPHIC (q22026earningspresentati034.jpg)

GRAPHIC (q22026earningspresentati035.jpg)

GRAPHIC (q22026earningspresentati036.jpg)

GRAPHIC (q22026earningspresentati037.jpg)

GRAPHIC (q22026earningspresentati038.jpg)

GRAPHIC (q22026earningspresentati039.jpg)

GRAPHIC (wgs-20260803_g1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: wgs-20260803.htm · Sequence: 1

wgs-20260803

0001818331false00018183312026-08-032026-08-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 3, 2026

Commission file number 001-39482

GeneDx Holdings Corp.

(Exact name of registrant as specified in its charter)

Delaware

85-1966622

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

333 Ludlow Street, North Tower; 6th Floor

Stamford, Connecticut 06902

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (888) 729-1206

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol Name of each exchange on which registered

Class A common stock, par value $0.0001 per share WGS The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 3, 2026, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the quarter ended June 30, 2026. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No

Description

99.1

Press Release, dated August 3, 2026, regarding the registrant’s results for the quarter ended June 30, 2026

99.2

Earnings Presentation, dated August 3, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEDX HOLDINGS CORP.

Date: August 3, 2026 By: /s/ Katherine Stueland

Name: Katherine Stueland

Title: Chief Executive Officer

EX-99.1

Filename: exhibit991-q22026pressrele.htm · Sequence: 2

Document

Exhibit 99.1

GeneDx Reports Second Quarter 2026 Financial Results

•Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue

•Reported exome and genome volume growth of 32% year-over-year

•Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million

•Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30%

•Hosting conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., August 3, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026.

“Our team’s unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability” said Katherine Stueland, CEO of GeneDx. “We are managing the transition to genome testing, making progress on each of our key imperatives — optimizing unit economics, growing utilization, and delivering the best products at unmatched scale — while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible.”

Second Quarter 2026 Financial Results (Unaudited)(1)

Revenue

•Revenue grew to $114.4 million, an increase of 11% year-over-year.

•Exome and genome test revenue grew to $100.3 million, an increase of 17% year-over-year.

Exome and genome volume

•Exome and genome test result volume grew to 30,785, an increase of 32% year-over-year.

Gross margin

•Adjusted gross margin of 70% in the second quarter of 2026 is up from 69% in the first quarter of 2026 and compares to 71% in the second quarter of 2025.

◦GAAP gross margin was 68%.

Operating expenses

•Adjusted total operating expenses were $80.3 million, representing 70% of revenue.

◦Total GAAP operating expenses were $95.7 million.

Net income

•Adjusted net income was $0.4 million, up $8.6 million from the first quarter of 2026 and compared to adjusted net income of $16.4 million in the second quarter of 2025.

◦GAAP net loss was $17.7 million.

Cash position

•Cash, cash equivalents, marketable securities and restricted cash was $133.5 million as of June 30, 2026.

•On August 3, 2026, the Company amended and restated its existing loan agreement with Blackstone, adding an additional $50.0 million term loan facility and increasing the aggregate principal amount available under the facility to $150.0 million. Concurrently, an affiliate of Blackstone agreed to purchase approximately $5.0 million of the Company’s Class A common stock at $61.00 per share in a private placement.

◦Combined with the cash, cash equivalents, marketable securities and restricted cash balance of $133.5 million as of June 30, 2026, the Company’s pro forma cash position following this transaction is approximately $188 million.

(1)Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.

GeneDx 2026 Guidance

GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026. Management expects GeneDx to deliver:

Metric Full Year 2026 Guidance Third Quarter 2026 Guidance

Revenue

$475 to $490 million

$122 to $124 million

Exome and genome volume

At least 30% growth

33,200 tests

Exome and genome revenue

At least 20% growth

$110 to $112 million

Adjusted gross margin

Approximately 70%

Adjusted net income

Positive

Approximately $2 million

Second Quarter 2026 and Recent Business Highlights

Strategic Expansion and Market Leadership

•Appointed Mark Gardner as President to lead GeneDx’s commercial and operations teams through the next phase of growth, with a focus on strengthening execution, scaling efficiently, and expanding the company’s leadership in genomic medicine.

•Launched redesigned exome and genome reports to streamline the delivery of genomic insights to non-genetics clinicians as part of a broader suite of customer experience improvements rolling out this summer.

Expanded Coverage for Exome and Genome

•Improved access to exome sequencing in Texas with new Medicaid coverage effective May 1, 2026, building on existing genome sequencing coverage in the state.

•Received California Medicaid (Medi-Cal) pricing for genome sequencing effective July 1, 2026, with pricing published at 100% of the Medicare rate. Coverage for genome sequencing in California was originally announced as effective November 1, 2025.

•Secured outpatient genome sequencing coverage from Carelon, the nation’s largest lab benefit manager, opening access to up to 56 million covered lives. The policy is effective June 14, 2026.

•Expanded the total number of state Medicaid programs covering outpatient exome and/or genome sequencing to 39 following Mississippi Medicaid’s announcement of coverage for both tests effective July 1, 2026.

Innovation and Clinical Leadership

•Contributed to 26 peer-reviewed publications, 41 conference presentations, and 50 abstracts in the first half of 2026, reflecting the depth and breadth of the Company’s scientific expertise and its commitment to moving the field forward.

Webcast and Conference Call Details

GeneDx will host a conference call today, August 3, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.

Non-GAAP Financial Measures

GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, non-core lease costs, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year and third quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) future expansion of insurance coverage for exome and genome testing. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 3, 2026, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Investor Relations Contact:

Investors@GeneDx.com

Media Contact:

Press@GeneDx.com

Volume & Revenue

2Q26 1Q26 4Q25 3Q25 2Q25

Volumes

Whole exome, whole genome 30,785 27,488 27,761 25,702 23,246

Other panels 32,057 27,729 31,281 34,514 34,510

Total 62,842 55,217 59,042 60,216 57,756

Revenue ($ millions)

Whole exome, whole genome $ 100.3 $ 90.6 $ 104.0 $ 98.9 $ 86.0

Other panels 11.6 10.7 13.3 14.6 14.1

Data information 2.3 0.8 2.6 1.5 2.0

Software and interpretation services

0.2 0.2 1.1 1.7 0.6

Total $ 114.4 $ 102.3 $ 121.0 $ 116.7 $ 102.7

Unaudited Select Financial Information

Three months ended June 30, 2026

Reported Depreciation and amortization Stock-based compensation Restructuring costs Change in FV of financial liabilities

Other(2)

Adjusted

Diagnostic test revenue $ 111,886 $ — $ — $ — $ — $ — $ 111,886

Other revenue 2,554 — — — — — 2,554

Total revenue 114,440 — — — — — 114,440

Cost of services 36,202 (1,726) (561) (47) — — 33,868

Gross profit

78,238 1,726 561 47 — — 80,572

Gross margin 68.4 % 70.4 %

Research and development 19,656 (271) (1,387) (1,036) — — 16,962

Selling, general and administrative 76,037 (4,717) (4,394) (2,212) — (1,353) 63,361

(Loss) income from operations

(17,455) 6,714 6,342 3,295 — 1,353 249

Interest expense, net

(1,185) — — — — 1,185 —

Other income (expense), net 382 — — — (220) — 162

Income tax benefit 518 — — — — (518) —

Net (loss) income

$ (17,740) $ 6,714 $ 6,342 $ 3,295 $ (220) $ 2,020 $ 411

Basic (loss) earnings per share(1)

$ (0.60) $ 0.01

Diluted (loss) earnings per share(1)

$ (0.60) $ 0.01

Three months ended June 30, 2025

Reported Depreciation and amortization Stock-based compensation Restructuring costs Change in FV of financial liabilities

Other(2)

Adjusted

Diagnostic test revenue $ 100,100 $ — $ — $ — $ — $ — $ 100,100

Other revenue 2,592 — — — — — 2,592

Total revenue 102,692 — — — — — 102,692

Cost of services 31,790 (1,389) (193) — — — 30,208

Gross profit

70,902 1,389 193 — — — 72,484

Gross margin 69.0 % 70.6 %

Research and development 15,079 (209) (1,422) — — — 13,448

Selling, general and administrative 46,863 (4,593) (6,198) (73) — 6,937 42,936

Income from operations 8,960 6,191 7,813 73 — (6,937) 16,100

Interest expense, net

(817) — — — — 817 —

Other income (expense), net 2,420 — — — (2,181) 49 288

Income tax benefit 246 — — — — (246) —

Net income $ 10,809 $ 6,191 $ 7,813 $ 73 $ (2,181) $ (6,317) $ 16,388

Basic earnings per share(1)

$ 0.38 $ 0.57

Diluted earnings per share(1)

$ 0.36 $ 0.55

(1)Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,710,139 weighted average shares outstanding and Diluted adjusted earnings per share are calculated based on 30,144,132 weighted average shares outstanding for the three months ended June 30, 2026. Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively.

(2)Other represents interest expense, net, income tax benefit and non-core lease costs for all periods presented. For the three months ended June 30, 2026, Other also includes costs related to legal reserves. For the three months ended June 30, 2025, Other includes transaction costs incurred in connection with the acquisition of Fabric Genomics and a sales-and-use tax refund.

Unaudited Select Financial Information

Three months ended March 31, 2026

Reported Depreciation and amortization Stock-based compensation Restructuring costs Change in FV of financial liabilities Extinguishment

of debt

Other(2)

Adjusted

Diagnostic test revenue $ 101,299 $ — $ — $ — $ — $ — $ — $ 101,299

Other revenue 955 — — — — — — 955

Total revenue 102,254 — — — — — — 102,254

Cost of services 34,043 (1,462) (380) — — — — 32,201

Gross profit 68,211 1,462 380 — — — — 70,053

Gross margin 66.7 % 68.5 %

Research and development 19,804 (224) (1,406) (224) — — — 17,950

Selling, general and administrative 74,591 (5,123) (7,210) (215) — — (1,916) 60,127

Impairment loss 31,287 — — — — — (31,287) —

Loss from operations (57,471) 6,809 8,996 439 — — 33,203 (8,024)

Interest expense, net (717) — — — — — 717 —

Other (expense) income, net (4,231) — — — (2,540) 6,565 — (206)

Income tax expense (897) — — — — — 897 —

Net loss $ (63,316) $ 6,809 $ 8,996 $ 439 $ (2,540) $ 6,565 $ 34,817 $ (8,230)

Basic and diluted loss per share(1)

$ (2.16) $ (0.28)

(1)Basic and diluted loss per share are calculated based on 29,335,126 weighted average shares outstanding for the three months ended March 31, 2026.

(2)For the three months ended March 31, 2026, Other represents interest expense, net, income tax expense and non-core lease costs, costs related to legal reserves, and impairment of goodwill and intangible assets associated with the Fabric Genomics acquisition.

GeneDx Holdings Corp.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30, 2026 (Unaudited) December 31, 2025

Assets:

Current assets:

Cash and cash equivalents $ 60,317 $ 104,997

Marketable securities 72,231 66,285

Accounts receivable 83,610 74,370

Inventory, net 17,820 13,951

Prepaid expenses and other current assets 12,382 8,685

Total current assets 246,360 268,288

Operating lease right-of-use assets 33,535 23,412

Property and equipment, net 54,316 45,693

Goodwill 1,641 13,520

Intangible assets, net 141,350 168,481

Other assets(1)

4,284 4,316

Total assets $ 481,486 $ 523,710

Liabilities and Stockholders’ Equity:

Current liabilities:

Accounts payable and accrued expenses $ 42,091 $ 57,645

Short-term lease liabilities 5,709 4,404

Other current liabilities 26,828 46,859

Total current liabilities 74,628 108,908

Long-term debt, net of current portion 96,836 48,176

Long-term lease liabilities 64,857 56,046

Other liabilities 71 1,641

Deferred taxes 873 757

Total liabilities 237,265 215,528

Stockholders’ Equity:

Preferred stock — —

Class A common stock 3 3

Additional paid-in capital 1,698,427 1,680,738

Accumulated deficit (1,454,551) (1,373,495)

Accumulated other comprehensive income 342 936

Total stockholders’ equity 244,221 308,182

Total liabilities and stockholders’ equity $ 481,486 $ 523,710

(1)Other assets includes $1.0 million of restricted cash as of both June 30, 2026 and December 31, 2025.

GeneDx Holdings Corp.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

Three months ended June 30, Six months ended June 30,

2026 2025 2026 2025

Revenue

Diagnostic test revenue $ 111,886 $ 100,100 $ 213,185 $ 185,859

Other revenue 2,554 2,592 3,509 3,948

Total revenue 114,440 102,692 216,694 189,807

Cost of services 36,202 31,790 70,245 60,429

Gross profit 78,238 70,902 146,449 129,378

Research and development 19,656 15,079 39,460 27,656

Selling, general and administrative 76,037 46,863 150,628 97,313

Impairment loss — — 31,287 —

(Loss) income from operations (17,455) 8,960 (74,926) 4,409

Non-operating (expense) income, net

Change in fair value of financial liabilities 220 2,181 2,760 1,081

Interest expense, net (1,185) (817) (1,902) (1,457)

Loss on extinguishment of debt — — (6,565) —

Other income (expense), net 162 239 (44) 448

Total non-operating (expense) income, net (803) 1,603 (5,751) 72

(Loss) income before income taxes (18,258) 10,563 (80,677) 4,481

Income tax benefit (expense) 518 246 (379) (201)

Net (loss) income $ (17,740) $ 10,809 $ (81,056) $ 4,280

Weighted-average shares outstanding of Class A common stock - Basic 29,710,139 28,579,704 29,523,669 28,365,018

Basic (loss) earnings per share, Class A common stock $ (0.60) $ 0.38 $ (2.75) $ 0.15

Weighted-average shares outstanding of Class A common stock - Diluted

29,710,139 29,753,933 29,523,669 29,642,555

Diluted (loss) earnings per share, Class A common stock

$ (0.60) $ 0.36 $ (2.75) $ 0.14

GeneDx Holdings Corp.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

Six months ended June 30,

2026 2025

Operating activities

Net (loss) income $ (81,056) $ 4,280

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

Depreciation and amortization expense 13,523 11,869

Stock-based compensation expense 15,338 11,796

Change in fair value of financial liabilities (2,760) (1,081)

Deferred tax expense 379 202

Change in third party payor reserves (1,022) 5,014

Loss on extinguishment of debt 6,565 —

Impairment loss 31,287 —

Other 2,157 1,510

Change in operating assets and liabilities:

Accounts receivable (9,240) (9,889)

Inventory (3,973) (1,404)

Accounts payable and accrued expenses (12,566) 7,199

Other assets and liabilities (20,021) (8,894)

Net cash (used in) provided by operating activities (61,389) 20,602

Investing activities

Acquisition of business, net of cash acquired — (33,195)

Purchases of marketable securities (29,065) (30,770)

Proceeds from sales of marketable securities 2,272 —

Proceeds from maturities of marketable securities 20,475 26,705

Purchases of property and equipment and development of internal-use software

(16,567) (8,498)

Net cash used in investing activities (22,885) (45,758)

Financing activities

Proceeds from long term debt, net of issuance costs 96,699 —

Proceeds from offerings, net of issuance costs — 13,766

Proceeds from issuance of common stock from subscription agreements 476 —

Proceeds from issuance of common stock pursuant to employee stock purchase plan 1,793 1,262

Exercise of stock options 58 800

Repayment of long-term debt, including prepayment penalty - Perceptive (54,000) —

Repayment and principal payments for long-term debt - DECD (4,447) (602)

Finance lease principal payments (984) (1,162)

Net cash provided by financing activities 39,595 14,064

Net decrease in cash, cash equivalents and restricted cash

(44,679) (11,092)

Cash, cash equivalents and restricted cash, at beginning of period 105,989 86,202

Cash, cash equivalents and restricted cash, at end of period (1)

$ 61,310 $ 75,110

Supplemental disclosures of cash flow information

Cash paid for interest $ 3,813 $ 3,210

Cash paid for taxes $ 2,221 $ 920

Lease liability from obtaining right-of-use asset $ 12,086 $ —

Purchases of property and equipment in accounts payable and accrued expenses $ 3,154 $ 5,752

(1)Cash, cash equivalents and restricted cash as of June 30, 2026 excludes marketable securities of $72.2 million.

EX-99.2

Filename: q22026earningspresentati.htm · Sequence: 3

q22026earningspresentati

GeneDx Nasdaq: WGS Q2 2026 Earnings Presentation August 2026 Exhibit 99.2

2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including expectations for full year and third quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income (loss). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this presentation, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) future expansion of insurance coverage for exome and genome testing. The foregoing list of factors is not exhaustive. The information, opinions and forward-looking statements contained in this announcement is not exhaustive and speak only as of its date and are subject to change without notice. This presentation contains estimates, projections and other information concerning our industry, our business and the markets for our products and services. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. We discuss these and other risks and uncertainties in greater detail in the sections entitled “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports and other filings we make with the SEC from time to time. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. We file reports, proxy statements, and other information with the SEC. Such reports, proxy statements, and other information concerning us are available www.sec.gov. Requests for copies of such documents should be directed to our Investor Relations department at GeneDx Holdings Corp. 333 Ludlow Street, North Tower 6th Floor, Stamford, Connecticut, 06902. Our telephone number is 888-729-1206. Non-GAAP Financial Measures This presentation includes certain financial measures not presented in accordance with generally accepted accounting principles in the United States ("GAAP"), which are used by management as a supplemental measure, have certain limitations, and should not be construed as alternatives to financial measures determined in accordance with GAAP. The non-GAAP measures as defined by us may not be comparable to similar non-GAAP measures presented by other companies. Our presentation of such measures, which may include adjustments to exclude unusual or non-recurring items, should not be construed as an inference that our future results will be unaffected by other unusual or non-recurring items. A reconciliation is provided in the Appendix to the most directly comparable financial measure stated in accordance with GAAP.

3 Q2 2026 Results Metric Second Quarter 2026 Revenue $114.4 million Exome and genome volume 30,785 Exome and genome revenue $100.3 million Adjusted gross margin1 70% Adjusted net income1 $0.4 million Cash on hand Pro forma cash on hand2 $133.5 million Approximately $188 million 1 Adjusted gross margin and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented. 2. Giving rise to expected net proceeds upon close of the Blackstone Life Sciences debt expansion and equity investment transaction announced August 3, 2026.

4 Strong demand drove exome and genome volume growth Exome and genome volume year-over-year: • Q2 2026 YoY: up 32% to 30,785 • Unit growth was broad- based across geneticists, pediatric neurology, and NICU 30,785 Q1 2025 Exome and Genome Volume Q2 2025 Q3 2025 Q4 2025 Q1 2026 0 5,000 10,000 15,000 20,000 25,000 30,000 Q2 2024 Q3 2024 Q4 2024 18,017 Q2 2026 23,246

5 Revenue growth rebounded as mix shift toward genome moderated $100.3 Q1 2025 Exome and Genome Revenue (in $M) Q2 2025 Q3 2025 Q4 2025 Q1 2026 0 $20 $86.0 Q2 2024 Q3 2024 Q4 2024 $50.7 Exome and genome revenue year-over year: • Q2 2026 YoY: up 17% to $100.3M • Q2 ARR: ~$3,250 • Primary driver of YoY ARR variability is product mix shift into whole genome $40 $60 $80 $100 $120 Q2 2026

6 We've organized the company around three key imperatives Optimize unit economics Deliver the leading products at unmatched scale Grow utilization of exome and genome

7 Focused on four operational levers to improve blended average reimbursement rates Manage Mix Expand Payer Coverage Invest In Technology Implement Payer-Specific Workflows1 3 2 4

8 2026 Guidance Metric Full Year 2026 Guidance Third Quarter 2026 Guidance Revenue $475 to $490 million $122 to $124 million Exome and genome volume At least 30% growth 33,200 tests Exome and genome revenue At least 20% growth $110 to $112 million Adjusted gross margin1 Approximately 70% Approximately 70% Adjusted net income1 Positive Approximately $2 million 1 Adjusted gross margin and adjusted net income are non-GAAP financial measures.

9 Confidential & Proprietary. Do Not Distribute. Appendix

10 Empowering everyone to live their healthiest life through genomics

11 GeneDx is the global leader in rare disease diagnosis The largest and most diverse rare disease dataset to deliver highest accuracy Diagnosing more rare disease patients than anyone else and delivering 500+ new gene-disease discoveries over 25 years Preferred by 80% of geneticists and granted FDA Breakthrough Device designation The #1 genetic test Experience & TechnologyGeneDx InfinityTM 1. GeneDx Internal Data, data on file 2026 2. Claims data provided by Definitive Healthcare

12 An accurate genetic diagnosis is key to transforming healthcare Enabling precision genomic medicine Providing an early and accurate genetic diagnosis Fueling drug discovery

13 Delivering the future of precision medicine via the network effect Biopharma Accelerating drug discovery, enabling clinical trials, and unlocking biomarkers for targeted therapies with real-world evidence Policymakers Improving population health outcomes with support for evidence-based policies driving innovation and efficiencies Patients Delivering faster, more accurate diagnosis with personalized treatments based on biology, leading to better outcomes Health Systems Improving clinical decisions, streamlining care pathways, and reducing costs with genomic insights Payers Reducing long-term spend through effective, targeted treatments supporting value-based care models with measurable outcomes Advocacy Delivering answers for families, advancing equitable care, and connecting patients and parents across rare and underserved communities

14 Trusted by the nation’s leading health systems

15 >2.5M >50% >8M ~1M >8M >60% genetic tests non-European descent health records exomes & genomes phenotypic datapoints have parental data GeneDx InfinityTM is the largest and most diverse rare disease dataset Greatest scale advantage Fastest diagnosis and most efficient operations Most comprehensive understanding of rare disease Billions of datapoints inform expert analysis The most accurate diagnosis 2x the answers compared to public datasets 1. GeneDx Internal Data, data on file 2026

16 Our AI strategy accelerates the flywheel effect of our data Additional patients tested Improved interpretation platform Higher diagnostic yields and more answers More underlying data N A T U R A L L A N G U A G E P R O C E S S I N G M A C H I N E L E A R N I N G L A R G E L A N G U A G E M O D E L S Creating the Lab of the Future to translate cutting-edge innovation into better patient outcomes The compounding power of the data from each new patient informs more diagnoses and extends our lead Proprietary AI models and algorithms constantly enhance our accuracy, scale, speed, and efficiency

17 Upside Opportunities International, Biopharma/Data, Precision Medicine Pediatrics & Rare Pediatric Specialists, Pediatricians, NICU, Prenatal, and gNBS Adult Adult Neurologists, Adult Cardiologists, and Other Specialists $25B $20B This large and ever-growing opportunity is ours to win

18 On average, an accurate diagnosis takes 5 years GeneDx provides answers in months weeks days hours First symptom Visit primary care physician Referral to a specialist Genetic testing (CMA) No diagnosis Online research Another specialist Wrong treatment or undue surgery Genetic testing (panel) Inconclusive results New symptoms Genetic specialist Genetic counseling Order exome or genome DiagnosisDisease specific care and resources The economic burden of rare diseases in the U.S. is over $1 trillion annually 1. Marwaha S, Knowles JW, and Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022 Feb 28;14(1):23. 2. Tisdale, A., Cutillo, C.M., Nathan, R. et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis 16, 429 (2021).

19 We are monitoring key metrics that translate to higher blended ARR over time Payer Policy CoverageProduct Mix Commercial Covered Lives Genome Q2 outpatient genome mix 98% 90% 87% 47% Exome Q1 Q2 Q1 Q2 Q2 outpatient genome volume submitted to payers with an active positive coverage policy Collection Rate Q2 collection rate for outpatient genome 1 3 2 39 23 37 State Medicaid Policies Cover outpatient exome and/or genome Cover outpatient exome Cover outpatient genome

20 Medicaid programs across the country are expanding access 1. GeneDx Internal Data, data on file 2026 Exome Coverage Only Genome Coverage Only Exome and Genome Coverage No Coverage Current Medicaid Coverage Landscape New or Enhanced Coverage

21 Our north star is to diagnose as many people as fast as possible

22 Our stacked, compounding growth strategy unlocks new opportunities Foundational Markets (Launched) Expansion Markets (Ramping) Future Markets (Developing) • Geneticists (since inception) • Pediatric Specialists (since 2023) • General Pediatricians (H2 2026) • NICU (since 2024) • Prenatal (H2 2026) • Adult Specialists (H2 2026) • International (since 2025) • gNBS • New Channels • BioPharma & Data Three layers, multiple building blocks to sustained high growth with disciplined expansion plan

23 Core markets of geneticists and pediatric neurologists continued to perform well while expansion markets gain momentum 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Geneticsits Pediatric Specialists Prenatal NICU Adult specialists General Pediatrics Clinician Penetration by Market 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Geneticsits Pediatric Specialists Prenatal NICU Adult specialists General Pediatrics Patient Penetration by Market 5K2K 800 accounts 10.5K 25K4.6K ti ist enetici ts S i li t S 145K300K 235K160K 600K210K Number of U.S. PatientsNumber of U.S. Clinicians

24 GeneticistPrenatal Standard of care: years of disease progression Pediatrician Entering new markets to deliver answers at the earliest moment possible NICU Adult Specialist Pediatric Specialist

25 Geneticists remain key customers and prefer GeneDx Geneticist recommendations reinforce our leadership in new markets Leading position: 80% market share driven by superior accuracy, broad access, and cutting-edge discovery Continued growth: Largest contributor to revenue today with room to grow via ongoing panel conversion Loyal advocates: As we continue to expand, these ~2,000 geneticists are key influencers for other clinicians 1. GeneDx Internal Data, data on file 2026 2. Claims data provided by Definitive Healthcare Foundational Market

26 Pediatric specialists continue drive high growth Significant share: Over 30% of pediatric neurologists now order from us with continued growth ahead Strong awareness: Greatest brand recognition of any genetics lab - over 80% of pediatric specialists know GeneDx Expanding our footprint: Continuing to add new call points and indications to serve the over 10,000 rare diseases Increased ordering and new customer activation driving expansion 1. GeneDx Internal Data, data on file 2026 2. Claims data provided by Definitive Healthcare 3. Fu MP, Merrill SM, Sharma M,et al. Rare diseases of epigenetic origin: Challenges and opportunities. Front Genet. 2023 Feb 6;14:1113086. doi: 10.3389/fgene.2023.1113086. PMID: 36814905. Foundational Market

27 Pediatricians are becoming the new front line of genomic medicine Massive market: 600K patients diagnosed with DD/ID by 25K pediatricians annually First mover to an untapped market with the #1 genetic test in hand Trusted partner & clear leader: Leading product, wraparound services, expert endorsements, and health system relationships Best customer experience: Pediatricians can integrate genomics into routine care with one-minute ordering Expansive reach: Dedicated team of ~50 sales reps expected to drive impact at the end of 2026 and into 2027 1. GeneDx Internal Data, data on file 2026 2. Claims data provided by Definitive Healthcare Expansion Market

28 The NICU is an untapped opportunity for early intervention and improved outcomes Taking a protocol-driven approach to benefit more patients and lower healthcare costs Large unmet need: Up to 60% NICU patients could benefit from rWGS per SeqFirst (~235k patients) but less than 5% of them receive genetic testing today 1. Wenger TL, Scott A, Kruidenier L, et al. SeqFirst: Building equity access to a precise genetic diagnosis in critically ill newborns. Am J Hum Genet. 2025 Mar 6;112(3):508-522. 2. Claims data provided by Definitive Healthcare 3. Kingsmore, Stephen F et al. NPJ genomic medicine vol. 9,1 17. 27 Feb. 2024 4. GeneDx Internal Data, data on file 2026 Deep relationships: 42 of the top 50 NICUs ordered rapid testing from us in 2025, positioning us to scale Fastest TAT: Leading rapid and ultrarapid genome tests deliver precise answers in as soon as 48 hours Expansion Market

29 GenomeDx Prenatal extends our industry-leading diagnostic capabilities into prenatal care Setting a new standard for prenatal genomic diagnoses Large unmet need: For patients with structural anomalies on prenatal ultrasound, impacting up to 4% of pregnancies Extensive prenatal experience: Building upon 10+ years of experience offering CMA and 4000+ prenatal exomes Timely answers: Delivering the most accurate and comprehensive diagnostic results in less than two weeks to guide critical care decisions 1.Salomon LJ, Alfirevic Z, Berghella V, et al. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. Ultrasound Obstet Gynecol. 2011 Jan;37(1):116-26. 2. GeneDx Internal Data, data on file 2026 Expansion Market

30 Adult specialists will unlock future growth and impact Putting commercial focus behind the organic growth in adult exome and genome testing New market: Expanding to neurologists in 2026 with a focus on clinicians already ordering genetic testing Green space: Strong demand and reimbursement for adults living with pediatric-onset conditions like epilepsy Long-term potential: Future opportunities could expand to cardiology, neurodegenerative disorders, and more, representing up to 5M patients 1. GeneDx Internal Data, data on file 2026 2. Claims data provided by Definitive Healthcare Expansion Market

31 Global reach with decentralized testing powered by centralized intelligence from GeneDx InfinityTM Cloud-native platform enables remote interpretation while complying with local regulations Providing leading interpretation services to key domestic partners Expanded international footprint with sales reps in key geographies Expansion Market

32 Transforming healthcare from diagnostic odyssey to day one action with gNBS GeneDx has the evidence, experience, and operational capabilities to lead global adoption • Partnering with first movers to make gNBS a reality o GUARDIAN o BEACONS o Sunshine Genetics • Without gNBS, the average age of diagnosis for these conditions is 7-11 years old Data from the GUARDIAN study: • Nearly 75% of parents opted into testing • Implemented diverse multi- site programs Evidence Experience Capabilities • Actionable conditions identified in 3.2% of newborns • Sequenced >22,000 newborns • Operations optimized for accuracy, speed, and scale • Flexible services – from end- to-end testing to decentralized interpretation • Technical expertise to responsibly bring this technology to patients 1. Ziegler A, Koval-Burt C, Kay DM, et al. Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions. JAMA. Published online October 24, 2024. doi:10.1001/jama.2024.1966 2. GeneDx Internal Data, data on file 2026 Future Market

33 Pioneering new channels and partnerships to deliver on the promise of precision genomic medicine Future Market

34 Unlocking faster HEOR, biopharma innovation, and AI-driven discovery Genetic data Electronic health records Patient demographics Claims Prescription Imaging Deploying the most comprehensive, longitudinal dataset for rare disease ever assembled Future Market

35 Turning insight into biopharma impact

36 Proven leadership driving high-growth and operational excellence at scale Heidi Chen Chief Legal Officer Linda Genen Chief Medical Officer Jami Biliboaca Head of People Strategy Katherine Stueland Chief Executive Officer Kevin Feeley Chief Financial Officer Melanie Duquette Chief Growth Officer Mark Gardner President Lisa Gurry Chief Business Officer Bryan Dechairo Chief Operating Officer

37 Massive TAM and expanding serviceable market Leadership position Differentiated technology A rare opportunity to transform healthcare fueled by unmatched data and momentum Emerging guidelines and improving payer landscape Scale advantage Proven management team

38 Our core competitive advantage compounds with every patient we test. We are setting the industry standard, delivering actionable answers for families and sustainable value for shareholders.

39 Reconciliation of non-GAAP financial measures Adjusted gross profit, adjusted gross margin, and adjusted net income (loss) (in $ thousands) Three months ended June 30, 2026 June 30, 2025 March 31, 2026 Revenue $ 114,440 $ 102,692 $ 102,254 Cost of services 36,202 31,790 34,043 Gross profit $ 78,238 $ 70,902 $ 68,211 Gross margin 68.4% 69.0% 66.7% Reconciliations: Depreciation and amortization expense 1,726 1,389 1,462 Stock-based compensation expense 561 193 380 Restructuring charges 47 – – Adjusted gross profit $ 80,572 $ 72,484 $ 70,053 Adjusted gross margin 70.4% 70.6% 68.5% (in $ thousands) Three months ended June 30, 2026 June 30, 2025 March 31, 2026 Net (loss) income $ (17,740) $ 10,809 $ (63,316) Reconciliations: Depreciation and amortization expense 6,714 6,191 6,809 Stock-based compensation expense 6,342 7,813 8,996 Restructuring costs 3,295 73 439 Change in fair value of financial liabilities (220) (2,181) (2,540) Interest expense, net 1,185 817 717 Non-core lease costs 1,097 1,405 1,210 Impairment loss – – 31,287 Loss on extinguishment of debt – – 6,565 Other1 (262) (8,539) 1,603 Adjusted net income (loss) $ 411 $ 16,388 $ (8,230) 1 Other represents income tax benefit (expense) for all periods presented. For the three months ended June 30, 2026, Other includes costs related to certain litigation matters. For the three months ended June 30, 2025, Other includes transaction costs incurred in connection with the acquisition of Fabric Genomics, and a sales-and-use tax refund. For the three months ended March 31, 2026, Other includes costs related to a certain litigation matter.

GRAPHIC

Filename: genedxlogo.jpg · Sequence: 7

Binary file (17936 bytes)

Download genedxlogo.jpg

GRAPHIC

Filename: q22026earningspresentati001.jpg · Sequence: 8

Binary file (36391 bytes)

Download q22026earningspresentati001.jpg

GRAPHIC

Filename: q22026earningspresentati002.jpg · Sequence: 9

Binary file (318201 bytes)

Download q22026earningspresentati002.jpg

GRAPHIC

Filename: q22026earningspresentati003.jpg · Sequence: 10

Binary file (90237 bytes)

Download q22026earningspresentati003.jpg

GRAPHIC

Filename: q22026earningspresentati004.jpg · Sequence: 11

Binary file (79236 bytes)

Download q22026earningspresentati004.jpg

GRAPHIC

Filename: q22026earningspresentati005.jpg · Sequence: 12

Binary file (87774 bytes)

Download q22026earningspresentati005.jpg

GRAPHIC

Filename: q22026earningspresentati006.jpg · Sequence: 13

Binary file (58675 bytes)

Download q22026earningspresentati006.jpg

GRAPHIC

Filename: q22026earningspresentati007.jpg · Sequence: 14

Binary file (70944 bytes)

Download q22026earningspresentati007.jpg

GRAPHIC

Filename: q22026earningspresentati008.jpg · Sequence: 15

Binary file (86148 bytes)

Download q22026earningspresentati008.jpg

GRAPHIC

Filename: q22026earningspresentati009.jpg · Sequence: 16

Binary file (28094 bytes)

Download q22026earningspresentati009.jpg

GRAPHIC

Filename: q22026earningspresentati010.jpg · Sequence: 17

Binary file (148558 bytes)

Download q22026earningspresentati010.jpg

GRAPHIC

Filename: q22026earningspresentati011.jpg · Sequence: 18

Binary file (132856 bytes)

Download q22026earningspresentati011.jpg

GRAPHIC

Filename: q22026earningspresentati012.jpg · Sequence: 19

Binary file (65810 bytes)

Download q22026earningspresentati012.jpg

GRAPHIC

Filename: q22026earningspresentati013.jpg · Sequence: 20

Binary file (117710 bytes)

Download q22026earningspresentati013.jpg

GRAPHIC

Filename: q22026earningspresentati014.jpg · Sequence: 21

Binary file (115111 bytes)

Download q22026earningspresentati014.jpg

GRAPHIC

Filename: q22026earningspresentati015.jpg · Sequence: 22

Binary file (89975 bytes)

Download q22026earningspresentati015.jpg

GRAPHIC

Filename: q22026earningspresentati016.jpg · Sequence: 23

Binary file (117422 bytes)

Download q22026earningspresentati016.jpg

GRAPHIC

Filename: q22026earningspresentati017.jpg · Sequence: 24

Binary file (70463 bytes)

Download q22026earningspresentati017.jpg

GRAPHIC

Filename: q22026earningspresentati018.jpg · Sequence: 25

Binary file (108053 bytes)

Download q22026earningspresentati018.jpg

GRAPHIC

Filename: q22026earningspresentati019.jpg · Sequence: 26

Binary file (108715 bytes)

Download q22026earningspresentati019.jpg

GRAPHIC

Filename: q22026earningspresentati020.jpg · Sequence: 27

Binary file (84709 bytes)

Download q22026earningspresentati020.jpg

GRAPHIC

Filename: q22026earningspresentati021.jpg · Sequence: 28

Binary file (43478 bytes)

Download q22026earningspresentati021.jpg

GRAPHIC

Filename: q22026earningspresentati022.jpg · Sequence: 29

Binary file (86809 bytes)

Download q22026earningspresentati022.jpg

GRAPHIC

Filename: q22026earningspresentati023.jpg · Sequence: 30

Binary file (94866 bytes)

Download q22026earningspresentati023.jpg

GRAPHIC

Filename: q22026earningspresentati024.jpg · Sequence: 31

Binary file (71214 bytes)

Download q22026earningspresentati024.jpg

GRAPHIC

Filename: q22026earningspresentati025.jpg · Sequence: 32

Binary file (109070 bytes)

Download q22026earningspresentati025.jpg

GRAPHIC

Filename: q22026earningspresentati026.jpg · Sequence: 33

Binary file (105600 bytes)

Download q22026earningspresentati026.jpg

GRAPHIC

Filename: q22026earningspresentati027.jpg · Sequence: 34

Binary file (122602 bytes)

Download q22026earningspresentati027.jpg

GRAPHIC

Filename: q22026earningspresentati028.jpg · Sequence: 35

Binary file (125434 bytes)

Download q22026earningspresentati028.jpg

GRAPHIC

Filename: q22026earningspresentati029.jpg · Sequence: 36

Binary file (124485 bytes)

Download q22026earningspresentati029.jpg

GRAPHIC

Filename: q22026earningspresentati030.jpg · Sequence: 37

Binary file (112762 bytes)

Download q22026earningspresentati030.jpg

GRAPHIC

Filename: q22026earningspresentati031.jpg · Sequence: 38

Binary file (114928 bytes)

Download q22026earningspresentati031.jpg

GRAPHIC

Filename: q22026earningspresentati032.jpg · Sequence: 39

Binary file (139953 bytes)

Download q22026earningspresentati032.jpg

GRAPHIC

Filename: q22026earningspresentati033.jpg · Sequence: 40

Binary file (120652 bytes)

Download q22026earningspresentati033.jpg

GRAPHIC

Filename: q22026earningspresentati034.jpg · Sequence: 41

Binary file (82012 bytes)

Download q22026earningspresentati034.jpg

GRAPHIC

Filename: q22026earningspresentati035.jpg · Sequence: 42

Binary file (90912 bytes)

Download q22026earningspresentati035.jpg

GRAPHIC

Filename: q22026earningspresentati036.jpg · Sequence: 43

Binary file (103260 bytes)

Download q22026earningspresentati036.jpg

GRAPHIC

Filename: q22026earningspresentati037.jpg · Sequence: 44

Binary file (88621 bytes)

Download q22026earningspresentati037.jpg

GRAPHIC

Filename: q22026earningspresentati038.jpg · Sequence: 45

Binary file (109771 bytes)

Download q22026earningspresentati038.jpg

GRAPHIC

Filename: q22026earningspresentati039.jpg · Sequence: 46

Binary file (135855 bytes)

Download q22026earningspresentati039.jpg

GRAPHIC

Filename: wgs-20260803_g1.jpg · Sequence: 47

Binary file (17936 bytes)

Download wgs-20260803_g1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 49

v3.26.1

Document and Entity Information Document

Aug. 03, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 03, 2026

Entity Registrant Name

GeneDx Holdings Corp.

Entity Incorporation, State or Country Code

Entity File Number

001-39482

Entity Tax Identification Number

85-1966622

Entity Address, Address Line One

333 Ludlow Street

Entity Address, City or Town

Stamford

Entity Address, State or Province

Entity Address, Postal Zip Code

06902

City Area Code

888

Local Phone Number

729-1206

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A common stock, par value $0.0001 per share

Trading Symbol

WGS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Address, Address Line Two

North Tower

Entity Address, Address Line Three

6th Floor

Entity Central Index Key

0001818331

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration